Immunology of cutaneous lupus erythematosus

Clinics in Dermatology

Volumn 22, Issue 2, 2004, Pages 105-112

  Angotti, Chiara ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Sezione di Reumatologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CELL ADHESION MOLECULE; CELL NUCLEUS ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PROTEIN DERIVATIVE; RECOMBINANT ALPHA2A INTERFERON; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLELISM; APOPTOSIS; CELL DEATH; CELL SURFACE; CLINICAL FEATURE; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; DNA DAMAGE; FRAGMENTATION REACTION; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; KERATINOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; PHOTOSENSITIVITY; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION RESPONSE; REVIEW; SKIN LUPUS ERYTHEMATOSUS; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; SKIN; ULTRAVIOLET RAYS;

EID: 3042652951     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2003.12.017     Document Type: Review

References (96)

1. Kielbassa C., Roza L., Epe B. Wavelength dependence of oxidative DNA damage induced by UV and visible light. Carcinogenesis. 18:1997;811-816
2. Epstein J., Tuffanelli D., Dubois E. Light sensitivity in lupus erythematosus. Arch Dermatol. 91:1965;483-485
3. Cripps D., Rankin J. Action spectra of lupus erythematosus and experimental immunofluorescence. Arch Dermatol. 107:1973;563-567
4. Kochevar I. Action spectrum and mechanism of UV-radiation induced injury in lupus erythematosus. J Invest Dermatol. 85:1985;140S-143S
5. Nived O., Johansen P.B., Sturfelt G. Standardized ultraviolet A exposure provokes skin reaction in systemic lupus erythematosus. Lupus. 2:1993;247-250
6. Lehmann P., Holzle E., Kind P., Goerz G., Plewig G. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol. 22:1990;181-187
7. Yell J., Wojnarowska F. Diagnosis and management of systemic lupus erythematosus. Sun protection is vital. Br Med J. 307:1993;939
8. Millard T.P., Hawk J.L., McGregor J.M. Photosensitivity in lupus. Lupus. 9:2000;3-10
9. Natali G.P., Tan E.M. Experimental renal disease induced by DNA-anti-DNA immune complexes. J Clin Invest. 51:1972;345-355
10. Sutherland B.M., Hacham H., Gange R.W., Maytum D., Sutherland J.C. DNA damage and repair in human skin pathways and questions. Basic Life Sci. 53:1990;149-160
11. Runger T.M., Epe B., Moller K. Processing of directly and indirectly ultraviolet-induced DNA damage in human cells. Recent Results Cancer Res. 139:1995;31-42
12. Davis P., Russell A.S., Percy J.S. Antibodies to UV light denatured DNA in systemic lupus erythematosus detection by filter radio-immunoassay and clinical correlations. J Rheumatol. 3:1976;375-379
13. LeFeber W.P., Norris D.A., Ryan S.R., et al. Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes. J Clin Invest. 74:1984;1545-1551
14. Furukawa F., Kashihara-Sawami M., Lyons M.B., Norris D.A. Binding of antibodies to the extractable nuclear antigens SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL) implications for the pathogenesis of photosensitive cutaneous lupus. J Invest Dermatol. 94:1990;77-85
15. Golan T.D., Elkon K.B., Gharavi A.E., Krueger J.G. Enhanced membrane binding of auto antibodies to cultured keratinocytes of systemic lupus erythematosus patients after ultraviolet B/ultraviolet A irradiation. J Clin Invest. 90:1992;1067-1076
16. Norris D.A. Pathomechanisms of photosensitive lupus erythematosus. J Invest Dermatol. 100:1993;58S-68S
17. Furukawa F., Itoh T., Wakita H., et al. Keratinocytes from patients with lupus erythematosus show enhanced cytotoxicity to ultraviolet radiation and to antibody-mediated cytotoxicity. Clin Exp Immunol. 118:1999;164-170
18. Casciola-Rosen L., Rosen A. Ultraviolet light-induced keratinocyte apoptosis a potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus. 6:1997;175-180
19. Norris D.A., Whang K., David-Bajar K., Bennion S.D. The influence of ultraviolet light on immunological cytotoxicity in the skin. Photochem Photobiol. 65:1997;636-646
20. Chiodino C., Cesinaro A.M., Ottani D., et al. Communication expression of the novel inhibitor of apoptosis surviving in normal and neoplastic skin. J Invest Dermatol. 113:1999;415-418
21. Deveraux Q.L., Reed J.C. IAP family proteins - suppressors of apoptosis. Genes Dev. 3:1999;239-252
22. Daniels F.J. Histochemical responses of human skin following ultraviolet radiation. J Invest Dermatol. 37:1961;351-356
23. Godar D.E. UVA1 radiation triggers two different final apoptotic pathways. J Invest Dermatol. 112:1999;3-12
24. Bollain-y-Goytia J.J., Avalos-Diaz E., Herrera-Esparza R. Fas ligand and Bax gene transcription contributes to Ro60 ribonucleoprotein redistribution in UV-A irradiated human keratinocytes. Joint Bone Spine. 67:2000;283-289
25. Aragane Y., Kulms D., Metze D., et al. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol. 140:1998;171-182
26. Hill L.L., Ouhtit A., Loughlin S.M., et al. Fas ligand a sensor for DNA damage critical in skin cancer etiology. Science. 285:1999;898-900
27. Casciola-Rosen L.A., Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 179:1994;1317-1330
28. Tan E.M. Autoimmunity and apoptosis. J Exp Med. 179:1994;1083-1086
29. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:1998;86-89
30. Casciola-Rosen L.A., Anhalt G.J., Rosen A. DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. J Exp Med. 182:1995;1625-1634
31. Utz P.J., Anderson P. Life and death decisions regulation of apoptosis by proteolysis of signaling molecules. Cell Death Differ. 7:2000;589-602
32. 1 T cells undergoing apoptosis a mechanism for T cell clearance during resolution of viral infections. J Exp Med. 180:1994;1943-1947
33. Korb L.C., Ahearn J.M. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes complement deficiency and systemic lupus erythematosus revisited. J Immunol. 158:1997;4525-4528
34. Eggleton P., Ward F.J., Johnson S., et al. Fine specificity of auto antibodies to calreticulin epitope mapping and characterization. Clin Exp Immunol. 120:2000;384-391
35. Nepomuceno R.R., Henschen-Edman A.H., Burgess W.H., Tenner A.J. cDna cloning and primary structure analysis of C1qR(P), the human C1q/Mbl/Spa receptor that mediates enhanced phagocytosis in vitro. Immunity. 6:1997;119-129
36. Taylor P.R., Carugati A., Fadok V.A., et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med. 192:2000;359-366
37. Botto M., Dell'Agnola C., Bygrave A.E., et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet. 19:1998;56-59
38. Bennion S.D., Norris D.A. Ultraviolet light modulation of autoantigens, epidermal cytokines and adhesion molecules as contributing factors of the pathogenesis of cutaneous LE. Lupus. 6:1997;181-192
39. Nishigori C., Yarosh D.B., Ullrich S.E., et al. Evidence that DNA damage triggers interleukin 10 cytokine production in UV-irradiated murine keratinocytes. Proc Natl Acad Sci USA. 93:1996;10354-10359
40. Grether-Beck S., Olaizola-Horn S., Schmitt H., et al. Activation of transcription factor AP-2 mediates UVA radiation- and singlet oxygen-induced expression of the human intercellular adhesion molecule 1 gene. Proc Natl Acad Sci USA. 93:1996;14586-14591
41. Dorner T., Hucko M., Mayet W.J., et al. Enhanced membrane expression of the 52 kDa Ro(SS-A) alpha. Ann Rheum Dis. 54:1995;904-909
42. Sampaio E.P., Sarno E.N., Galilly R., et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 173:1991;699-703
43. McHugh S.M., Rowland T.L. Thalidomide and derivatives immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol. 110:1997;151-154
44. Stephansson E., Ros A.M. Expression of intercellular adhesion molecule-1 (ICAM-1) and OKM5 in UVA- and UVB-induced lesions in patients with lupus erythematosus and polymorphous light eruption. Arch Dermatol Res. 285:1993;328-333
45. Dustin M.L., Singer K.H., Tuck D.T., Springer T.A. Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon gamma and is mediated by intercellular adhesion molecule 1 (ICAM-1). J Exp Med. 167:1988;1323-1340
46. Turksen K., Kupper T., Degenstein L., et al. Interleukin 6 insights to its function in skin by overexpression in transgenic mice. Proc Natl Acad Sci USA. 89:1992;5068-5072
47. Beissert S., Hosoi J., Grabbe S., et al. IL-10 inhibits tumor antigen presentation by epidermal antigen presenting cells. J Immunol. 154:(3):1995;1280-1286
48. Rivas J.M., Ullrich S.E. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol. 149:1992;3865-3871
49. Wang B., Zhuang L., Fujisawa H., et al. Enhanced epidermal Langerhans cell migration in IL-10 knockout mice. J Immunol. 162:1999;277-283
50. 1 T cell-B cell antibody synthesis. J Clin Immunol. 16:1996;198-207
51. Llorente L., Zou W., Levy Y., et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 181:1995;839-844
52. Morita A., Grewe M., Grether-Beck S., et al. Induction of proinflammatory cytokines in human epidermoid carcinoma cells by in vitro ultraviolet A1 irradiation. Photochem Photobiol. 65:1997;630-635
53. Kondo S., Jimbow K. Dose-dependent induction of IL-12 but not IL-10 from human keratinocytes after exposure to ultraviolet light A. J Cell Physiol. 177:1998;493-498
54. Shen J., Bao S., Reeve V.E. Modulation of IL-10, IL-12, and IFNgamma in the epidermis of hairless mice by UVA (320-400 nm) and UVB (280-320 nm) radiation. J Invest Dermatol. 113:1999;1059-1064
55. Carroll J.M., Crompton T., Seery J.P., Watt F.M. Transgenic mice expressing IFN-gamma in the epidermis have eczema, hair hypopigmentation, and hair loss. J Invest Dermatol. 108:1997;412-422
56. Seery J.P., Carroll J.M., Cattell V., Watt F.M. Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis. J Exp Med. 186:1997;1451-1459
57. Seery J.P., Wang E.C., Cattell V., et al. A central role for alpha beta T cells in the pathogenesis of murine lupus. J Immunol. 162:1999;7241-7248
58. Norris P., Poston R.N., Thomas D.S., et al. The expression of endothelial leukocyte adhesion molecule- 1 (ELAM-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in experimental cutaneous inflammation a comparison of ultraviolet B erythema and delayed hypersensitivity. J Invest Dermatol. 96:1991;763-770
59. Nyberg F., Hasan T., Skoglund C., Stephansson E. Early events in ultraviolet light-induced skin lesions in lupus erythematosus expression patterns of adhesion molecules ICAM-1, VCAM-1 and E-selectin. Acta Derm Venereol. 79:1999;431-436
60. Barker J.N., Sarma V., Mitra R.S., et al. Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest. 85:1990;605-608
61. Belmont H.M., Buyon J., Giorno R., Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum. 37:1994;376-383
62. Jones S.M., Mathew C.M., Dixey J., et al. VCAM-1 expression on endothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localized scleroderma. Br J Dermatol. 135:1996;678-686
63. Sontheimer R.D. Photoimmunology of Lupus erytematosus and dermatomyositis. Photochem Photobiol. 63:1996;583-594
64. Nyberg F., Hasan T., Puska P., et al. Occurrence of polymorphous light eruption in lupus erytematosus. Br J Dermatol. 136:1997;217-221
65. Watson R.M., Talwar P., Alexander E., et al. Subacute cutaneous lupus erythematosus-immunogenetic associations. J Autoimmun. 4:1991;73-85
66. Price P., Witt C., Allcock R., et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev. 167:1999;257-274
67. Provost T.T., Watson R. Anti-Ro (SS-A) HLA-DR3-positive women the interrelationship between some ANA negative, SS, SCLE, and NLE mothers and SS/LE overlap female patients. J Invest Dermatol. 100:1993;14S-20S
68. Harley R.B., Reichlin M., Arnett F.C., et al. Gene interaction at HLA-DQ enhances autoantibody production in primary Sjogren's syndrome. Science. 232:1986;1145-1147
69. Millard L.G., Rowell N.R., Rajah S.M. Histocompatibility antigens in discoid and systemic lupus erythematosus. Br J Dermatol. 96:1977;139-144
70. Knop J., Bonsmann G., Kind P., et al. Antigens of the major histocompatibility complex in patients with chronic discoid lupus erythematosus. Br J Dermatol. 122:1990;723-728
71. Tongio M.M., Fersing J., Hauptmann G., et al. HLA antigens in discoid lupus erythematosus. Acta Derm Venereol (Stockh). 62:1982;155-157
72. Provost T.T., Arnett F.C., Reichlin M. Homozygous C2 deficiency, lupus erythematosus, and anti-Ro (SSA) antibodies. Arthritis Rheum. 26:1983;1279-1282
73. Callen J.P., Hodge S.J., Kulick K.B., et al. Subacute cutaneous lupus erythematosus in multiple members of a family with C2 deficiency. Arch Dermatol. 123:1987;66-70
74. Braathen L.R., Bratlie A., Teisberg P. HLA genotypes in a family with a case of homozygous C2 deficiency and discoid lupus erythematosus. Acta Derm Venereol. 66:1986;419-422
75. Meyer O., Hauptmann G., Tappeiner G., et al. Genetic deficiency of C4, C2 or C1q and lupus syndromes. Association with anti-Ro (SS-A) antibodies. Clin Exp Immunol. 62:1985;678-684
76. Walport M.J., Davies K.A., Morley B.J., Botto M. Complement deficiency and autoimmunity. Ann NY Acad Sci. 815:1997;267-281
77. Sullivan K.E., Wooten C., Schmeckpeper B.J., et al. A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans. Arthritis Rheum. 40:1997;2207-2211
78. Rood M.J., van Krugten M.V., Zanelli E., et al. TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 43:2000;129-134
79. Bennion S.D., Middleton M.H., David-Bajar K.M., et al. In three types of interface dermatitis, different patterns of expression of intercellular adhesion molecule-1 (ICAM-1) indicate different triggers of disease. J Invest Dermatol. 105:1995;71S-79S
80. Werth V., Sullivan K. Strong association of a promoter polymorphism of tumor necrosis factor-alpha with a photosensitive form of cutaneous lupus erythematosus. Arthritis Rheumat. 42:1999;S105
81. Wilson A.G., de Vries N., Pociot F., et al. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 177:1993;557-560
82. Bigler C.F., Norris D.A., Weston W.L., Arend W.P. Interleukin-1 receptor antagonist production by human keratinocytes. J Invest Dermatol. 98:1992;38-44
83. Suzuki H., Matsui Y., Kashiwagi H. Interleukin-1 receptor antagonist gene polymorphism in Japanese patients with systemic lupus erythematosus. Arthritis Rheum. 40:1997;389-390
84. Blakemore A.I., Tarlow J.K., Cork M.J., et al. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum. 37:1994;1380-1385
85. Azarus M., Hajeer A.H., Turner D., et al. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol. 24:1997;2314-2317
86. Lorente L., Richaud-Patin Y., Couderc J., et al. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum. 40:1997;1429-1435
87. A der Linden M.W., Westendorp R.G., Sturk A., et al. High interleukin-10 production in first-degree relatives of patients with generalized but not cutaneous lupus erythematosus. J Investig Med. 48:2000;327-334
88. Furner B.B. Treatment of subacute cutaneous lupus erythematosus. Int J Dermatol. 29:1990;542-547
89. Knopp J., Bonsmann G., Happle R., et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. J Dermatol. 108:1983;461-466
90. Ochonisky S., Verroust J., Bastuji-Garin S., et al. Thalidomide neuropathy incident and clinicoelectrophysiologic finding in 42 patients. Arch Derm. 130:1994;66-69
91. Goldberg J.W., Lidsky M.D. Pulse methylprednisolone therapy for persistent subacute cutaneous lupus. Arthritis Rheum. 27:1984;837-838
92. Boehm I.B., Boehm C.A., Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate indication for modulation of inflammatory mechanisms. Rheumatol Int. 18:1998;59-62
93. Callen J.P., Spencer L.V., Bhatnagar Burruss J., et al. Azathioprine an effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus. Arch Dermatol. 127:1991;515-522
94. Nicolas J.-F., Thivolet J., Kanitakis J., et al. Response of discoid and subacute cutaneous lupus erythematosus or recombinant interferon alpha 2a. J Invest Dermatol. 95:1990;142S-145S
95. Thivolet J., Nicolas J.-F., Nicolas J.-F., et al. Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus. J Invest Dermatol. 122:1990;405-409
96. Prinz J.C., Meurer M., Reiter C., et al. Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. Am Acad Dermatol. 34:1996;244-252